U.S. markets closed
  • S&P Futures

    4,390.00
    -3.75 (-0.09%)
     
  • Dow Futures

    34,844.00
    +10.00 (+0.03%)
     
  • Nasdaq Futures

    14,984.75
    -26.75 (-0.18%)
     
  • Russell 2000 Futures

    2,222.10
    +1.40 (+0.06%)
     
  • Crude Oil

    72.32
    -0.07 (-0.10%)
     
  • Gold

    1,807.80
    +8.10 (+0.45%)
     
  • Silver

    25.08
    +0.20 (+0.80%)
     
  • EUR/USD

    1.1846
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    1.2610
    +0.0270 (+2.19%)
     
  • Vix

    18.31
    -1.05 (-5.42%)
     
  • GBP/USD

    1.3902
    -0.0007 (-0.05%)
     
  • USD/JPY

    109.8080
    -0.1020 (-0.09%)
     
  • BTC-USD

    39,879.59
    +697.88 (+1.78%)
     
  • CMC Crypto 200

    933.08
    +3.15 (+0.34%)
     
  • FTSE 100

    7,016.63
    +20.55 (+0.29%)
     
  • Nikkei 225

    27,719.97
    +138.31 (+0.50%)
     

Merck Completes Women's Health Organon Spinoff

·1 min read
  • In a move to free up a cash windfall and streamline the business, Merck & Co Inc (NYSE: MRK) had long planned to slice away its women’s health business into a standalone spinoff.

  • As of Thursday, that spinoff, dubbed Organon, is now a public entity all its own. Organon & Co. (NYSE: OGN) debuted on the NYSE.

  • As a part of the spinoff, Merck will receive a $9 billion special tax-free dividend that it will use for a future acquisition.

  • Organon is focused on Nexplanon, a long-active reversible contraceptive that has a patent expiring in 2027.

  • Last year, its sales were around $680 million. The company said it could boost sales to more than $1 billion in 2021.

  • Price Action: MRK shares are down 3.3% at $73.36, while OGN is down 4.6% at $33.63 during the market session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.